Head-to-head · WeighScore
eMI Aesthetics vs Levers Health
The verdict
eMI Aesthetics takes it — 70.1/100 to 53.3/100.
eMI Aesthetics grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMI Aesthetics is a US direct-to-consumer telehealth brand offering doctor-guided GLP-1 weight loss programs to eligible patients in all 50 states.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | eMI Aesthetics | Levers Health |
|---|---|---|
| WeighScore | 70.1/100 | 53.3/100 |
| Grade | C | C |
| Scorecard rank | #110 | #469 |
| Semaglutide | $179/mo (all doses, compounded) | $247/mo (1.25 mg dose, compounded) |
| Tirzepatide | Not disclosed | $296/mo (5 mg dose, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #110 · C
Strengths
- Available to eligible patients in all 50 states
- Offers both semaglutide and tirzepatide, plus an oral semaglutide option
- Intake and provider visits run through OpenLoop Health, an established telehealth network
Where it loses points
- Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
- No fill pharmacy or named medical director is publicly listed
- Support appears limited to email, with no phone number or hours published
Graded #469 · C
Strengths
- Named LLC entity
- Microdose GLP-1 option marketed for longevity
- Both semaglutide and tirzepatide available
Where it loses points
- No LegitScript or PCAB accreditation
- No physical address disclosed
- State availability not disclosed
- FAQ and terms pages return 404
- Above-average pricing ($247-$396/mo); tirzepatide any-dose plan is $396/mo (only the up-to-5mg low-dose plan is $296)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.